Immuron Ltd
ASX:IMC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Brother Enterprises Holding Co Ltd
SZSE:002562
|
CN |
|
Danimer Scientific Inc
NYSE:DNMR
|
US |
|
PNE AG
XETRA:PNE3
|
DE |
|
Schrodinger Inc
NASDAQ:SDGR
|
US |
|
Sunyes Electronic Manufacturing Guangdong Holding Co Ltd
SZSE:002388
|
CN |
|
D
|
Devyser Diagnostics AB
STO:DVYSR
|
SE |
|
I
|
Inox Green Energy Services Ltd
NSE:INOXGREEN
|
IN |
|
Zhaoke Ophthalmology Ltd
HKEX:6622
|
CN |
|
Highwoods Properties Inc
NYSE:HIW
|
US |
|
C
|
Chengdu Bright Eye Hospital Co Ltd
SZSE:301239
|
CN |
|
E
|
Enel Chile SA
SGO:ENELCHILE
|
CL |
Immuron Ltd
Long-Term Debt
Immuron Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immuron Ltd
ASX:IMC
|
Long-Term Debt
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Long-Term Debt
$66m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Long-Term Debt
$10.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Long-Term Debt
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Long-Term Debt
AU$448.4m
|
CAGR 3-Years
258%
|
CAGR 5-Years
215%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Long-Term Debt
AU$436.9k
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Immuron Ltd
Glance View
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.
See Also
What is Immuron Ltd's Long-Term Debt?
Long-Term Debt
0
AUD
Based on the financial report for Dec 31, 2025, Immuron Ltd's Long-Term Debt amounts to 0 AUD.
